Contingency table of the validated local diagnosis vs final study diagnosis
| Validated local diagnosis . | Final study diagnosis . | |||||||
|---|---|---|---|---|---|---|---|---|
| MDS . | MDS/MPN overlap . | ICUS . | AML with <30% blasts∗ . | Other AML . | Other malignancy . | Other . | Total . | |
| MDS | 209 | 10 | 8 | 2 | 1 | 3 | 22 | 255 |
| MDS/MPN overlap | 2 | 28 | 0 | 0 | 0 | 3 | 0 | 33 |
| ICUS | 8 | 2 | 32 | 0 | 0 | 3 | 11 | 56 |
| AML with <30% blasts | 0 | 0 | 0 | 12 | 0 | 0 | 0 | 12 |
| Other AML | 4 | 0 | 0 | 1 | 37 | 0 | 0 | 42 |
| Other malignancy | 2 | 0 | 0 | 0 | 0 | 80 | 0 | 82 |
| Other | 41 | 5 | 9 | 0 | 0 | 4 | 379 | 438 |
| Total | 266 | 45 | 49 | 15 | 38 | 93 | 412 | 918 |
| Agreement rate | 79% (209/266) | 62% (28/45) | 65% (32/49) | 80% (12/15) | 97% (37/38) | 86% (80/93) | 92% (379/412) | 85% (777/918) |
| κ (95% CI) | 0.78 (0.74-0.81) | |||||||
| Validated local diagnosis . | Final study diagnosis . | |||||||
|---|---|---|---|---|---|---|---|---|
| MDS . | MDS/MPN overlap . | ICUS . | AML with <30% blasts∗ . | Other AML . | Other malignancy . | Other . | Total . | |
| MDS | 209 | 10 | 8 | 2 | 1 | 3 | 22 | 255 |
| MDS/MPN overlap | 2 | 28 | 0 | 0 | 0 | 3 | 0 | 33 |
| ICUS | 8 | 2 | 32 | 0 | 0 | 3 | 11 | 56 |
| AML with <30% blasts | 0 | 0 | 0 | 12 | 0 | 0 | 0 | 12 |
| Other AML | 4 | 0 | 0 | 1 | 37 | 0 | 0 | 42 |
| Other malignancy | 2 | 0 | 0 | 0 | 0 | 80 | 0 | 82 |
| Other | 41 | 5 | 9 | 0 | 0 | 4 | 379 | 438 |
| Total | 266 | 45 | 49 | 15 | 38 | 93 | 412 | 918 |
| Agreement rate | 79% (209/266) | 62% (28/45) | 65% (32/49) | 80% (12/15) | 97% (37/38) | 86% (80/93) | 92% (379/412) | 85% (777/918) |
| κ (95% CI) | 0.78 (0.74-0.81) | |||||||
The number of participants assigned to each disease group crossclassified by assignment source is reported in this table, along with the agreement rates and κ statistics. Denominator in percentage represents the number participants reviewed that were assigned to disease group by final central study assignment.
AML with <30% blasts without core binding factor or acute promyelocytic leukemia.